NEWS>>>>>>>>>
Friday July 7, 7:01 am Eastern Time
Company Press Release
Advanced Viral Research Corp.'s Dr. Shalom Z. Hirschman Interviewed by CEOcast.com
YONKERS, NY--(BW HEALTHWIRE)--July 7, 2000--Shalom Z. Hirschman, MD, president and CEO of Advanced Viral Research Corp. (OTCBB:ADVR - news), has been interviewed by CEOcast.com (http://www.CEOcast.com), the premier source of original and syndicated streaming broadcast interviews of Chief Executive Officers at public and private news-making companies.
During the interview, Dr. Hirschman offers an overview of Advanced Viral Research Corp.'s mission and its research of Product R, a non-toxic peptide nucleic acid (PNA) immunomodulator being developed by the company as a broad-spectrum antiviral drug. Product R shows promise for the treatment of viral infections such as AIDS and Human Papilloma Virus (HPV), and autoimmune diseases like rheumatoid arthritis. Advanced Viral Research Corp. laboratory studies have shown that Product R inhibits the production of both the CCR5 and CXCR4 chemokine receptors, the key cellular co-receptors for the human immunodeficiency virus (HIV).
Research by scientists at The Advanced Viral Research Institute has also shown that Product R interferes with the expression of a key protein implicated in the development of cervical cancer (the product of the E7 gene of HPV subtype 18). Moreover, recent research has demonstrated that Product R interferes with the actual replication and growth of HPV in cell culture. These results indicate that Product R may be useful in the treatment of disseminated HPV infection and may interfere with the development of cervical cancer. Preliminary clinical results suggest that Product R may be an effective non-toxic drug for both systemic and topical therapy of disseminated HPV infection in people with AIDS.
Shalom Z. Hirschman, M.D., joined Advanced Viral Research Corp. as president and CEO following a 28-year affiliation with The Mt. Sinai School of Medicine and The Mt. Sinai Hospital. During his tenure there, Dr. Hirschman held several academic positions, including Director of the Division of Infectious Diseases, Professor of Medicine, and Vice Chairman of the Department of Medicine. He spent seven years at the National Institutes of Health in Bethesda, MD; he has been published in many peer-reviewed journals, including THE NEW ENGLAND JOURNAL OF MEDICINE, NATURE and SCIENCE, and founded one of New York City's first and most active AIDS treatment and research centers.
CEOcast's analysts average over 15 years experience covering and evaluating Wall Street's leading companies. CEOcast's programming is distributed to millions of on-line investors at over 700 financial web sites as well as to more than 20,000 portfolio managers, buy-side analysts and traders at more than 3,300 North American institutions. Content is also disseminated to over 7,000 investment research professionals representing over 425 institutions.
About Advanced Viral Research Corp.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm committed to researching, developing and bringing to market new, effective therapies for viral and other diseases, which will lead to the alleviation of human suffering and diseases worldwide. Its flagship drug, Product R, is a non-toxic immunomodulator that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS. |
